Henry Schein stock draws fresh interest after Russell 1000 change. Earnings growth and guidance frame the next phase

Henry Schein stock trades on Nasdaq with renewed attention after its removal from a Russell 1000 index, while solid first quarter 2026 results and full year guidance keep the focus on earnings power and healthcare distribution growth.

By Thomas Clarke, Operations & Strategy desk. Reviewed on June 30, 2026 at 2:35 p.m. ET.

Henry Schein Inc (ISIN US8064071025) is attracting renewed attention among US healthcare distributors after a recent index reshuffle and a solid start to 2026. According to an analysis on Henry Schein by Simply Wall St, the company was removed from a Russell 1000 index while its shares changed hands near $84.29, prompting investors to reassess valuation and long term growth prospects on the Nasdaq.

Index removal meets valuation debate

The immediate catalyst for fresh debate is the company’s removal from a Russell 1000 index, a move that can affect demand from index tracking funds and quantitative strategies. In its June 30, 2026 coverage, Simply Wall St highlights that Henry Schein’s exclusion from this benchmark has not prevented the stock from delivering a 30 day share price return of roughly 10.07% and a 90 day gain of about 15.40%, signaling resilient demand despite the index change.

The same analysis notes that Henry Schein’s one year total shareholder return stands near 13.17%, pointing to steadier compounding over a longer horizon even as the market digests the index removal. At a quoted price of about $84.29, Simply Wall St’s fair value model points to an intrinsic value of roughly $88.07, suggesting a modest undervaluation in the mid single digit percentage range. For many investors, that gap reinforces the idea that operational execution and earnings momentum may matter more than index membership over time.

Earnings beat and 2026 guidance

Beyond the index story, Henry Schein’s latest quarterly results provide a clearer operational backdrop. According to MarketBeat’s Henry Schein earnings summary, the company reported first quarter 2026 earnings per share of $1.32, beating the consensus estimate of $1.20 by $0.12 and underlining management’s ability to control costs and mix in a competitive distribution market.

The same MarketBeat overview notes that quarterly revenue rose 6.3% year over year to $3.37 billion, coming in slightly above the $3.34 billion that analysts had expected. On that basis, Henry Schein’s trailing earnings per share are reported at $3.31, corresponding to a price to earnings ratio of about 25.47 at recent prices, which positions the stock in a premium but not extreme range for a global healthcare distributor.

MarketBeat also cites the company’s full year 2026 earnings guidance, with management projecting EPS in a band of approximately $5.23 to $5.37, compared with a consensus forecast near $5.31. Revenue guidance is described in a corridor of around $13.6 billion to $13.8 billion against a consensus expectation of about $13.7 billion. That combination signals mid single digit to high single digit revenue expansion and high single digit earnings growth, providing a framework for investors evaluating the stock after the index change.

Dental and medical distribution at scale

Henry Schein’s core business model rests on distributing dental and medical products and services to office based practitioners worldwide, a scale driven platform that generates recurring demand and cash flow. The Simply Wall St profile of Henry Schein emphasizes that the company operates as a global provider of health care products and services, with a particular strength in dental supplies and equipment for small and mid sized practices, which tend to be more fragmented and service intensive than large hospital systems.

In practice, the company combines physical distribution centers, logistics capabilities and digital ordering platforms that allow dentists and physicians to source consumables, pharmaceuticals, small equipment and related services from a single partner. That structure is designed to simplify procurement for practices while giving Henry Schein purchasing leverage across thousands of SKUs and a broad supplier base. For investors, this kind of scale in a fragmented end market can support margin resilience through cycles, especially when backed by technology driven ordering and inventory management tools.

Henry Schein on Nasdaq and recent pricing

Henry Schein trades on the Nasdaq under the ticker HSIC, with recent analysis from Simply Wall St and MarketBeat referencing a price level around $84.29 as of late June 2026. The stock’s recent performance metrics cited by Simply Wall St, including a 10.07% return over 30 days and a 15.40% return over 90 days, suggest that investors have been willing to look through the Russell 1000 index removal and focus instead on earnings delivery and guidance.

Henry Schein at a glance

• Company: Henry Schein Inc.
• ISIN: US8064071025
• Ticker: HSIC
• Exchange: Nasdaq
• Price (as of June 29, 2026, 4:28 p.m. ET): $84.29 USD
• Market cap: mid-cap range in USD (as of June 29, 2026)
• Sector / Industry: Health Care Equipment & Supplies / Distribution
• Index membership: Member of U.S. healthcare sector benchmarks; removed from a Russell 1000 index in 2026
• Next earnings date: Estimated for early August 2026, not yet officially scheduled

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.